Clinical Trial: Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients

U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07709637) titled 'Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients' on July 12.

Brief Summary: The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of allogeneic SARS-CoV-2-Specific T cells (LB-DTK-COV19) in patients with persistent clinical symptoms following a positive SARS-CoV-2 PCR test for 14 days or longer. The main questions it aims to answer are:

* What is the maximum tolerated dose of LB-DTK-COV19 based on dose-limiting toxicity?

* What treatment emergent adverse events occur following LB-DTK-COV19 infusion?

* Does LB-DTK-COV19 result in c...